Global animal health company Huvepharma, after receiving Food & Drug Administration approval in July 2019 for Monovet 90, the first generic monensin available in the U.S., announced that it continues to expand the list of approved feed combinations with which Monovet can be fed.
Following the initial FDA combination approvals for use with Monovet 90 that were announced in mid-September, FDA approved on Oct. 11, 2019, additional drug feed additive combinations with Monovet 90 in the manufacture of Type B and C medicated feeds.
This most recent round of FDA approvals expands the use of Monovet 90 to be fed in combination with other feed additives commonly used in receiving rations for feedlot cattle, including decoquinate for coccidiosis prevention and tilmicosin for respiratory disease therapy, Huvepharma said. A list of all current medicated feed combinations approved with Monovet 90 is at www.monovet.us.
Glen Wilkinson, president of Huvepharma US, said, “We are very pleased about these additional combination approvals and appreciate the positive responses received from cattle producers and feeders in the industry about the expanded choices. Huvepharma's increasing product offerings brought to the livestock marketplace stems from years of dedicated effort put forth by our employees to provide our customers with relevant products that meet their needs.”
Huvepharma is a privately owned global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. Huvepharma is based in Sofia, Bulgaria, with the U.S. headquarters located in Peachtree City, Ga.
Although Huvepharma has only been active in the U.S. animal health market since 2005, the company began in Bulgaria more than 60 years ago. Huvepharma operates three facilities that utilize biosynthesis (fermentation) to manufacture active substances, nutritional supplements, enzymes, probiotics and ready medicinal formulations. It also constructed another state-of-the-art fermentation facility in Peshtera, Bulgaria, which opened this September. Huvepharma said this modern facility will increase its overall production capacity by 30% and ensures a consistent and ready supply of these products.